The randomized, double-blind, placebo-controlled study evaluated the impact of the firm’s Fortetropin ingredient on muscle protein synthesis in older men and women ranging in age from 60 to 75 years.
Myos Rens Technology Inc. (Cedar Knolls, NJ) announced top line results from an unpublished randomized, double-blind, placebo-controlled study evaluating the impact of the firm’s Fortetropin ingredient on muscle protein synthesis in older men and women ranging in age from 60 to 75 years. Conducted at the University of California, Berkeley and the University of Arkansas for Medical Sciences, 20 subjects were randomly assigned to consume either Fortetropin – a proprietary bioactive composition derived from fertilized egg yolk – or a macronutrient-matched placebo for 21 days.
After collecting a microbiopsy from each subject, researchers analyzed them to determine the fractional synthetic rate (FSR) of muscle proteins. Results showed that subjects taking Fortetropin saw an average FSR in several gene ontologies that were significantly higher to those taking placebo. This demonstrates the ingredient’s potential to improve the muscle health of older adults that are at risk of age-related muscle loss, called sarcopenia.
“We are committed to continuing scientific research to demonstrate the efficacy of our advanced nutrition products. This study shows Fortetropin’s remarkable potential for managing age-related muscle loss in older adults,” said Joseph Mannello, CEO of Myos Rens Technology, in a press release. “The results from this study will form the cornerstone of Myos’ ‘Healthy Aging’ business unit. The global elderly nutrition market was $19 billion in 2018 and is estimated to surpass $31 billion by 2026. We plan to aggressively move forward with additional clinical studies that will focus on this area along with recovery and rehabilitation.”